Clearance of Cutaneous Lichen Planus with Deucravacitinib.

Kyle Machynia, Jason E Hawkes

Abstract readCase Reports

In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Deucravacitinib in dermatology: current indication and existing off-label data.Drugs in context · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kyle MachyniaMr. Machynia is with the University of Nevada, Reno School of Medicine in Reno, Nevada.

Jason E HawkesDr. Hawkes is with the Oregon Medical Research Center and Oregon Health and Science University in Portland, Oregon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lichen planus (LP) is an idiopathic, immune-mediated inflammatory disorder commonly characterized by pruritic, violaceous papules and plaques that often involve the extremities. Although a variety of topical and systemic therapies are used, no targeted treatments are currently approved by the US Food and Drug Administration for this indication, and management of refractory disease remains challenging. Tyrosine kinase 2 (TYK2) inhibitors selectively modulate several cytokine signaling pathways, including interleukin (IL)-12, IL-23/IL-17, and type I interferon signaling, which are implicated in the pathogenesis of LP. Here, we report a case of biopsy-confirmed, treatment-refractory, cutaneous LP that achieved near-complete resolution after 2 months of therapy with the oral TYK2 inhibitor, deucravacitinib.

Indexed as

deucravacitinibJanus kinase signalingLichen planuspruritusTYK2 inhibition

Identifiers

PMID41890774

PMCPMC13016445

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.